Provider review · Published September 29, 2026 · Updated November 7, 2026
Dr. B review: the consultation price is not the price of the prescription
The current ED service separates clinical review from pharmacy payment, with state, video-review and refund qualifications.
Public-document editorial research · No clinician sign-off or firsthand treatment testing. Source access dates appear with each reference.
Updated November 7, 2026: corrected the medicine named in the pharmacy-price illustration and added questions for checking the service and quote. Earlier references and the original publication date are retained. No individual license or treatment result was independently verified.
Dr. B describes clinician review after an AI-assisted intake, with prescribing dependent on the assessment. Its ED consultation starts at $19; a required video review can cost more, and medicine is paid for separately. Those published details explain the service model without independently verifying a particular clinician or a patient’s experience.
A useful answer to “is Dr. B legitimate?” needs more than a familiar website or a low starting price. This review examines the public process and its limits, then identifies what to verify for a particular consultation. We did not enroll, request a prescription, inspect an individual license or make a pharmacy purchase.
AI-assisted intake still leads to a clinician’s decision
The ED service page describes an AI-assisted online consultation followed by review by a medical provider, either independently or during a video visit. Prescribing remains conditional on appropriateness. The terms distinguish the platform’s administrative role from independent medical practices providing clinical care.
It would therefore be inaccurate to describe the service as an AI system independently prescribing ED medicine. The useful service fact is the stated handoff to licensed clinical review. The Rex MD assessment provides a comparison with another virtual platform where a questionnaire, possible follow-up and a conditional prescription are different steps rather than a guaranteed result.
Nineteen dollars is the consultation starting point
Dr. B’s ED offer advertises a $19 consultation with no membership required. The same page says a brief video review may be needed because of state rules or the condition and treatment, at a slightly higher cost. A flat nineteen-dollar description without that qualification would overstate what the page promises.
The pharmacy charge is separate. The RedBox Rx review examines a contrasting arrangement in which choosing a different pharmacy can change a reduced visit fee. These differences are administrative, not evidence that either model produces better clinical outcomes. No selected video-review fee or personal treatment total was established here.
The pharmacy example has a medicine and quantity attached
The cost illustration identifies sildenafil 25 mg in a sixty-tablet quantity using a discount card. This pharmacy price example is not a dosing recommendation. Medicine costs depend on pharmacy and insurance; the consultation fee is separate. The example does not establish a universal price. We did not verify a selected quote or construct a treatment total. The price-per-order guide keeps these components distinct.
No required membership limits how the general terms apply
The terms contain provisions for subscriptions if a user elects one, including automatic renewal and cancellation. The ED page says membership is not required. It would be a mistake to import every general subscription clause into this particular consultation and describe it as a mandatory monthly ED plan.
The FAQ separately says the completed consultation fee cannot be refunded, with a support route for suspected errors or concerns. That matters even where the person does not have a recurring membership. The ZipHealth review shows another model in which whether a prescription is issued affects consultation-fee treatment differently.
Location matters at both the consultation and pharmacy stage
The FAQ describes consultations for adults eighteen or older physically located in the fifty states or Washington, DC. It also says prescriptions are sent only to pharmacies in the state where the person is currently located. Those are more useful access details than a loose statement that care is available from anywhere.
The same FAQ gives provider-review hours and recognizes that extra confirmation may be needed. The ED page’s three-hour review language should consequently remain an advertised timeframe rather than a guarantee. Geographic availability also does not establish that a particular condition, medication history or requested product is suitable for remote treatment in an individual case.
A catalog name does not settle an approved indication
The ED page lists several branded and generic choices and mentions Revatio alongside other treatments. It also discusses pulmonary hypertension when explaining tadalafil. Those mentions should not be read as proof that every named product is FDA-approved for ED or that different indications are interchangeable.
The specific Advagen sildenafil label concerns an oral ED tablet; it does not identify whatever a Dr. B clinician might prescribe or a chosen pharmacy might supply. The formula-evidence guide develops the wider lesson that a familiar active ingredient cannot replace a precise product record. This review makes no personal medicine-selection recommendation.
Continuing care extends beyond a successful prescription transfer
Dr. B’s ED page encourages continued primary care because ED can accompany other health concerns. Its FAQ says information is not automatically shared with a primary-care clinician without consent. A prescription reaching a pharmacy is therefore not evidence that every relevant clinician has received an updated record.
The page also retains interaction warnings and urgent responses for prolonged erections and vision or hearing loss. Provider popularity cannot answer those individual clinical questions; the testimonial-limits guide explains why. Dr. B documents a useful separation of consultation and medicine payment, while the exact video fee, pharmacy cost, record sharing and personal eligibility remain matters the public offer alone cannot settle.
The FAQ provides a route for requesting that information be shared. It does not confirm that a reader’s clinician has received it, reviewed it or accepted responsibility for subsequent follow-up.
Keep the clinical record and the price quote distinct
Before proceeding, write down the medical practice and clinician associated with the visit, the consultation amount you have accepted, and the pharmacy to which you want any resulting prescription sent. Ask for clarification of each missing item rather than treating the first displayed price as a completed order.
Then keep the consultation record and pharmacy quotation side by side. Label each amount by the service or item it covers, and note when the quote was obtained. This is a way to audit your own paperwork, not a promise that a quoted price or a requested treatment will be available. The price-per-order guide provides the comparison framework.
The current ED page, FAQ and terms were read for this update. The corrected illustration identifies an advertised item; it is not a dosing instruction.
Original sources
These documents support different kinds of statements. A provider page records an advertised offer; medical and regulatory records need their own exact-product context.
- Dr. B — erectile dysfunction careOfficial AI-assisted intake followed by medical-provider review; starting consultation, possible video charge and separate pharmacy examples do not establish a personal total. · Checked 2026-09-29
- Dr. B — terms of serviceOfficial administrative and independent medical-practice roles with optional subscription conditions; no mandatory recurring ED membership is inferred. · Checked 2026-09-29
- Dr. B — frequently asked questionsOfficial age, location, pharmacy, completed-consultation and record-sharing explanations; advertised review times and requested record transfers are not guaranteed outcomes. · Checked 2026-09-29
- DailyMed — sildenafil tablets, Advagen Pharma Ltd.Specific oral sildenafil ED tablet label updated January 7, 2026; contraindications and combination cautions provide product-specific context, not proof of a reviewed provider’s dispensed medicine or an approved compound. · Checked 2026-09-29
- Dr. B — ED careOfficial provider document · full public text retrieved · Checked 2026-11-07
- Dr. B — FAQOfficial provider document · full public text retrieved · Checked 2026-11-07
- Dr. B — termsOfficial provider document · full public text retrieved · Checked 2026-11-07